Mission Statement, Vision, & Core Values of Predictive Oncology Inc. (POAI)

Predictive Oncology Inc.'s Mission Statement, Vision, and Core Values are facing a critical stress test as the company executes a radical strategic pivot, moving from pure AI-driven drug discovery to a digital asset treasury strategy focused on AI infrastructure.

How does the core Vision-to bring hope to cancer patients-reconcile with a Q3 2025 operating revenue of only $3,618, while simultaneously holding a Strategic Compute Reserve of approximately $152.8 million in ATH tokens as of November 10, 2025? It's a massive financial tightrope walk, marked by a Q3 2025 net loss of $77.7 million, mostly a non-cash derivative liability, but still a jarring number.

Are the foundational values of scientific rigor and advancing effective cancer therapies still the defintely guiding light, or is the new reality of monetizing AI infrastructure a necessary, albeit complex, detour to fund the original mission?

Predictive Oncology Inc. (POAI) Overview

You need to understand that Predictive Oncology Inc. (POAI) is not a simple biotech play anymore; it's an AI-driven drug discovery company that has made a sharp, trend-aware pivot into the digital asset space to fund its core mission. The core business, founded in 2002, is leveraging Artificial Intelligence (AI) and machine learning (ML) to accelerate the development of cancer therapies, but the near-term financial story is all about their new Strategic Compute Reserve.

The company's original value proposition centers on its PeDAL™ platform, which pairs AI with the world's largest privately held biobank of over 150,000 tumor samples. This allows pharmaceutical partners to screen drug compounds against a massive, diverse set of human tumor samples much earlier in the discovery process. They also offer the ChemoFx® drug response assay, which saw a European launch and expanded US availability in the first quarter of 2025, plus proprietary 3D culture models for drug development.

Now, here's the quick math on their traditional sales: for the third quarter ended September 30, 2025, Predictive Oncology's operating revenue was just $3,618. That number tells you the core service business is still nascent, but it's the massive digital asset strategy that completely changes the risk/reward profile. You need to look at the whole picture, not just the legacy revenue line.

Q3 2025 Financial Performance: The Digital Asset Pivot

The latest financial reports for Q3 2025, released in November 2025, show a company in a radical transition. While the traditional operating revenue was minimal at $3,618, the company executed two private placements, raising approximately $50.8 million in cash and receiving in-kind ATH tokens-the native utility token of the Aethir network-with a notional value of about $292.7 million at the time of signing. That's the real headline.

This strategic shift into active digital asset management is intended to monetize AI infrastructure, a growing and capital-intensive market. To be fair, this move also created a massive, non-cash derivative liability of $74.4 million, resulting in a net loss of approximately $77.7 million for the quarter. That loss is a technical accounting charge, not an operational cash burn, and it's tied directly to the new asset class, so don't let it scare you away from the underlying strategy.

The key asset now sits on the balance sheet: as of November 10, 2025, Predictive Oncology held approximately 5.70 billion ATH tokens, with a market value of approximately $152.8 million. That's a substantial new treasury to fund their AI-driven oncology work. The strategic goal is to use this Strategic Compute Reserve to generate booked revenue and cash earnings by satisfying the growing enterprise demand for computing power.

• Q3 2025 Operating Revenue: $3,618
• Q3 2025 Net Loss: $77.7 million (non-cash charge was the driver)
• New Digital Assets (ATH): 5.70 billion tokens held
• Market Value of ATH (Nov 2025): Approximately $152.8 million

A Leading Position in AI-Driven Oncology and Compute

Predictive Oncology is defintely positioning itself at the confluence of two critical, high-growth sectors: AI-driven drug discovery and AI infrastructure. In the oncology space, their proprietary PeDAL™ platform and the sheer size of their biobank-the largest privately held collection globally-give them a distinct advantage in predicting drug efficacy and reducing development timelines. They are a science-driven company on the leading edge of oncology drug discovery, aiming to accelerate the time to identify preclinical candidates.

The bold move into digital asset management, leveraging the ATH token to create a Strategic Compute Reserve, introduces a second, high-potential revenue stream. This expansion addresses the global bottleneck in affordable and reliable AI infrastructure, a key issue for every company in the AI game. By becoming an operator on the Aethir ecosystem, Predictive Oncology is actively developing systems to monetize AI resources, giving them a unique dual-engine business model in a fiercely competitive market.

This dual focus-AI for cancer and AI for compute-is why analysts are paying close attention. To understand the full scope of this strategic pivot and the investors who are betting on this new model, you should check out Exploring Predictive Oncology Inc. (POAI) Investor Profile: Who's Buying and Why?

Predictive Oncology Inc. (POAI) Mission Statement

You're looking for the bedrock of a company, the thing that guides every tough decision, and for Predictive Oncology Inc. (POAI), that's their mission. It's not just a feel-good phrase; it's a strategic roadmap, especially when a company is navigating a complex transition, like their recent shift into digital asset management alongside their core science. Their mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer. This statement is the lens through which you must view their latest financial results, including the Q3 2025 net loss of $77.7 million, which was largely a non-cash charge tied to their new digital asset strategy, not a failure of their core science.

The mission has three critical components. Honestly, understanding these breaks down exactly how they plan to bring hope to cancer patients-their stated vision. If you want a deeper dive into their corporate history and how they make money, you can find it here: Predictive Oncology Inc. (POAI): History, Ownership, Mission, How It Works & Makes Money.

1. Changing the Landscape of Oncology Drug Discovery

The first core component is the big goal: to fundamentally change how cancer drugs are found and developed. The current system is slow, expensive, and frankly, broken-with 95% of all drugs failing clinical trials. POAI aims to eliminate the current trial-and-error approach for patients. They are doing this by aggressively pushing their validated flagship product, ChemoFx®, a live cell drug response assay, into the U.S. and launching it de novo in Europe.

This is a clear, near-term action. They are also focused on drug repurposing through a strategic collaboration with Every Cure. This effort uses AI to find new uses for existing, approved drugs, which is a much faster path to market. It's about getting effective treatments to the patient faster, period.

2. Harnessing Machine Learning and Scientific Rigor

The method is the second component: 'By harnessing the power of machine learning and scientific rigor.' This is where the company's value proposition gets technical, but it's simple to grasp. They pair artificial intelligence (AI) with the world's largest privately held biobank, which contains over 150,000 tumor samples. That's a massive, irreplaceable data set.

Their proprietary PeDAL™ platform uses this data to inform drug development. They also maintain a Clinical Laboratory Improvement Amendments (CLIA)-certified lab, which means their wet-lab science is held to rigorous US standards. This combination of cutting-edge AI and defintely high-quality lab work is what gives their predictions weight with pharmaceutical partners. Here's the quick math: AI needs data, and 150,000 samples is a lot of data.

• Pair AI with 150,000 tumor samples.
• Use the PeDAL™ platform for screening.
• Validate results in a CLIA-certified lab.

3. Improving the Probability of Success

The final component is the measurable outcome: 'we can improve the probability of success and advance drug compounds with a higher degree of confidence'. This is the financial analyst in me talking-it's all about de-risking the drug pipeline for partners. The average time to bring a drug to market is 12 years, but POAI's technology can accelerate the time to identify preclinical candidates up to 3x faster, often between 12 to 18 months.

This speed saves drug companies millions, but the confidence is the real kicker. Their PeDAL™ platform can predict if a cancer tumor sample will respond to a certain drug compound with a remarkable 92% accuracy. When you consider that their operating revenue for Q3 2025 was only $3.6 million, the potential revenue from successful, de-risked drug development partnerships is enormous. This high accuracy rate is the proof point for their entire mission, turning a long-shot gamble into an informed, confident investment.

Predictive Oncology Inc. (POAI) Vision Statement

You're looking for the true north of Predictive Oncology Inc. (POAI), especially now that their business model has shifted so dramatically. Here's the quick takeaway: their vision remains firmly rooted in oncology, but the financial engine driving that vision is now a dual-track strategy, pairing AI-driven drug discovery with a significant digital asset treasury.

The company's stated vision is simple and powerful: We bring hope to cancer patients. This is the emotional anchor, but to be fair, the real-world execution is now about two very different, yet financially intertwined, pillars: applying machine learning to drug discovery and monetizing high-performance computing assets.

The Vision: Bringing Hope to Cancer Patients

The core vision hasn't changed, even as the balance sheet has. It's about leveraging their proprietary PeDAL™ platform-which pairs artificial intelligence (AI) with the world's largest privately held biobank of over 150,000 tumor samples-to eliminate the historical trial-and-error approach in cancer treatment.

Their flagship product, ChemoFx®, a validated live cell drug response assay, is the most direct expression of this vision. It helps oncologists predict which chemotherapies are most likely to work for a patient's specific cancer, initially focusing on ovarian and other gynecological cancers. This is a defintely a high-impact, patient-first action.

• Eliminate trial-and-error in oncology.
• Expand ChemoFx® to new tumor types.
• Improve patient outcomes directly.

The Mission: Changing the Oncology Drug Discovery Landscape

Predictive Oncology's mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies. This requires scientific rigor and capital. The financial reality in Q3 2025 shows the challenge: operating revenue was only $3.6 million, nearly flat year-over-year, while the net loss ballooned to $77.7 million.

The mission is now being funded by a strategic pivot. They are using their AI expertise to create a Strategic Compute Reserve, which is essentially a digital asset treasury. This is how they plan to improve the probability of success-by securing the financial runway needed for long-term discovery work. You can read more about the company's operational history and financial moves here: Predictive Oncology Inc. (POAI): History, Ownership, Mission, How It Works & Makes Money.

Core Strategic Pillars: AI and Digital Asset Synergy

The company's near-term actions reveal their core values are now focused on leveraging AI infrastructure for both drug discovery and financial growth. The new digital asset strategy, announced in Q3 2025, is the most critical shift. They raised approximately $50.8 million in cash and secured an additional notional value of approximately $292.7 million in ATH tokens through private placements.

As of November 10, 2025, Predictive Oncology held about 5.70 billion ATH tokens, with a market value of approximately $152.8 million. This is a massive treasury shift. The goal is to monetize these assets through staking and GPU rentals within the Aethir ecosystem, targeting high single-digit returns by fiscal year 2026. This new pillar is all about generating the capital to fund the original oncology mission.

• Monetize AI infrastructure for capital.
• Hold 5.70 billion ATH tokens for treasury.
• Target high single-digit returns by FY'26.

Here's the quick math: the $74.4 million derivative liability recorded in Q3 2025 is a non-cash accounting charge tied directly to this new digital asset strategy, but it shows the scale and complexity of the new financial structure. The action for you is clear: track the yield and liquidity of those ATH holdings, because that's what's funding the hope for cancer patients.

Predictive Oncology Inc. (POAI) Core Values

You're looking for a clear map of what drives Predictive Oncology Inc. (POAI) beyond the quarterly numbers, and that's smart. The company's values are the bedrock for its strategy, especially in a volatile 2025. Their core mission-to change the landscape of oncology drug discovery-is supported by three clear, actionable values that dictate capital allocation and operational focus.

I see their commitment in two main areas: doubling down on their core AI/oncology technology and making a bold, strategic pivot to secure their financial future. This isn't just corporate fluff; it's where the money goes. You can delve deeper into the capital structure by Exploring Predictive Oncology Inc. (POAI) Investor Profile: Who's Buying and Why?

Patient-Centric Innovation

This value is about eliminating the costly and emotionally draining trial-and-error approach in cancer treatment. Predictive Oncology Inc. views its technology not just as a revenue generator, but as a tool to bring hope to cancer patients, which is their stated vision. They want oncologists to make better, faster treatment decisions from the start.

The company demonstrates this by aggressively pushing its flagship ChemoFx® live-cell drug response assay. This assay helps predict which chemotherapies are most likely to work on a patient's specific tumor. In 2025, the company continued preparations for an aggressive market expansion of ChemoFx® in the U.S. and is planning a de novo launch in Europe, which is defintely a big step for patient access.

• Focus on ovarian and other gynecological cancers first.
• Leverage a biobank of over 150,000 patient tumor samples.

They're putting their science where the patient need is greatest.

Scientific Rigor and Data-Driven Discovery

The core of Predictive Oncology Inc.'s business is the pairing of artificial intelligence (AI) and machine learning (ML) with the largest privately held biobank of tumor samples. This value means every decision, from drug discovery to market expansion, must be grounded in precise data and scientific validation. They don't guess; they use their proprietary PeDAL™ platform to predict drug response with up to 92% accuracy.

Here's the quick math on their R&D focus in 2025:

• Operations, research, and development expenses were approximately $499,715 for Q2 2025, showing a tight focus on core science.
• In Q1 2025, they successfully identified three abandoned drug compounds (Afuresertib, Alisertib, and Entinosta) that warrant further exploration for new colon and breast cancer indications, demonstrating the power of their AI-driven drug repurposing registry.
• They also successfully developed two distinct 3D liver toxicity models exclusively for Labcorp, a global leader in lab services, showcasing their advanced 3D tumor model capabilities.

This is a science company, so they have to show their work.

Strategic Agility and Financial Resilience

A company in a capital-intensive field like oncology drug discovery needs a deep commitment to financial resilience. This value became critically important in 2025 as the company executed a massive strategic shift to secure its balance sheet, moving beyond traditional biotech funding models. They are not afraid to pivot to create a foundation for future growth.

The most concrete example is the launch of their digital asset treasury strategy in Q3 2025, which involved a major investment in the Aethir (ATH) token ecosystem to monetize AI infrastructure. This move secured significant capital:

• Raised approximately $50.8 million in cash through two private placements.
• As of November 10, 2025, they held about 5.70 billion ATH tokens, with a market value of approximately $152.8 million.

This strategy aims to generate a high single-digit yield on their ATH tokens by fiscal year 2026, creating a non-dilutive revenue stream to fund their core oncology research. Plus, they reduced net cash used in operating activities of continuing operations to $4,280,632 in the first half of 2025, down from $5,504,158 in the prior year period. They are getting leaner while simultaneously making a huge new investment.